EP1805320A4 - Verfahren zur rückfaltung rekombinanter antikörper - Google Patents
Verfahren zur rückfaltung rekombinanter antikörperInfo
- Publication number
- EP1805320A4 EP1805320A4 EP05811874A EP05811874A EP1805320A4 EP 1805320 A4 EP1805320 A4 EP 1805320A4 EP 05811874 A EP05811874 A EP 05811874A EP 05811874 A EP05811874 A EP 05811874A EP 1805320 A4 EP1805320 A4 EP 1805320A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reinforcing
- recombinant antibodies
- recombinant
- antibodies
- reinforcing recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62129504P | 2004-10-22 | 2004-10-22 | |
| US70176205P | 2005-07-22 | 2005-07-22 | |
| PCT/US2005/038045 WO2006047340A2 (en) | 2004-10-22 | 2005-10-21 | Methods for refolding of recombinant antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP1805320A2 EP1805320A2 (de) | 2007-07-11 |
| EP1805320A4 true EP1805320A4 (de) | 2009-09-16 |
| EP1805320B1 EP1805320B1 (de) | 2014-09-03 |
Family
ID=36129791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05811874.6A Revoked EP1805320B1 (de) | 2004-10-22 | 2005-10-21 | Verfahren zur rückfaltung rekombinanter antikörper |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7928205B2 (de) |
| EP (1) | EP1805320B1 (de) |
| JP (2) | JP5553963B2 (de) |
| KR (1) | KR101370253B1 (de) |
| AU (1) | AU2005299716B2 (de) |
| BR (1) | BRPI0517457A (de) |
| CA (1) | CA2584211C (de) |
| EA (1) | EA012162B1 (de) |
| IL (1) | IL182626A0 (de) |
| MA (1) | MA29027B1 (de) |
| MX (1) | MX2007004437A (de) |
| NO (1) | NO20072571L (de) |
| NZ (1) | NZ554520A (de) |
| RU (1) | RU2007118954A (de) |
| SG (1) | SG156672A1 (de) |
| WO (1) | WO2006047340A2 (de) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1805320B1 (de) * | 2004-10-22 | 2014-09-03 | Amgen Inc. | Verfahren zur rückfaltung rekombinanter antikörper |
| KR101374454B1 (ko) * | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US7476852B2 (en) * | 2005-05-17 | 2009-01-13 | Honeywell International Inc. | Ionization-based detection |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| EP4793360A2 (de) * | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| CA2665567C (en) * | 2006-10-06 | 2012-07-03 | Amgen Inc. | Stable formulations |
| US7705132B2 (en) * | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| US20090311732A1 (en) * | 2006-12-22 | 2009-12-17 | Ares Trading S.A. | Analytical method for analyzing c-terminus truncation |
| EP2626372B1 (de) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispezifische Antikörper und Verfahren zu deren Herstellung |
| EP2586788B1 (de) | 2007-07-09 | 2017-11-29 | Genentech, Inc. | Verhindern der Disulfid-Bindungsreduktion während der rekombinanten Herstellung von Polypeptiden |
| JP5963341B2 (ja) * | 2007-09-14 | 2016-08-10 | アムジエン・インコーポレーテツド | 均質な抗体集団 |
| AU2016202036B2 (en) * | 2007-09-26 | 2017-12-07 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| RU2505603C2 (ru) | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| EP3127921A1 (de) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr |
| TWI548418B (zh) | 2007-12-05 | 2016-09-11 | 中外製藥股份有限公司 | Anti-NR10 / IL-31RA antibody and its use |
| UA99339C2 (ru) * | 2008-03-12 | 2012-08-10 | Имклоун Ллк | Антитело, которое специфично связывает человеческий tyrp1 |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| EP2282769A4 (de) * | 2008-04-29 | 2012-04-25 | Abbott Lab | Dual-variable- domain-immunglobuline und ihre verwendungen |
| KR20110016959A (ko) * | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2297209A4 (de) * | 2008-06-03 | 2012-08-01 | Abbott Lab | Dual-variable- domain-immunglobuline und ihre verwendungen |
| US8822645B2 (en) * | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| AU2009283678B2 (en) * | 2008-08-19 | 2014-01-16 | Glytech, Inc. | Glycoprotein production method and screening method |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | 中外製藥股份有限公司 | Antibody constant region change body |
| CA2759370C (en) * | 2009-04-30 | 2020-02-11 | Peter Schotte | Method for the production of domain antibodies |
| BRPI1012195A2 (en) * | 2009-05-01 | 2018-04-24 | Abbott Laboratories | double variable domain immunoglobulins and their uses |
| CN102459344A (zh) | 2009-05-15 | 2012-05-16 | 中外制药株式会社 | 抗axl抗体 |
| SG176963A1 (en) | 2009-06-22 | 2012-02-28 | Amgen Inc | Refolding proteins using a chemically controlled redox state |
| LT3660032T (lt) | 2009-06-25 | 2026-02-25 | Amgen Inc. | Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| EP2483289B2 (de) | 2009-10-02 | 2025-03-26 | Biogen MA Inc. | Verfahren zur vorbeugung und entfernung von trisulphid-bindungen |
| AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2543730B1 (de) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Variante einer konstanten antikörperregion |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| US9631216B2 (en) | 2011-04-29 | 2017-04-25 | Biocon Research Limited | Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof |
| US9562252B2 (en) | 2011-05-13 | 2017-02-07 | Biogen Ma Inc. | Methods of preventing and removing trisulfide bonds |
| IN2014CN03887A (de) | 2011-10-27 | 2015-10-16 | Genmab As | |
| CA2857194A1 (en) * | 2011-12-07 | 2013-06-13 | Thomas M. Dillon | Igg2 disulfide isoform separation |
| AR089529A1 (es) | 2011-12-30 | 2014-08-27 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 |
| SG11201407809QA (en) | 2012-05-31 | 2014-12-30 | Agency Science Tech & Res | Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities |
| PE20151179A1 (es) | 2012-11-01 | 2015-09-12 | Abbvie Inc | Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas |
| AU2014226126B2 (en) | 2013-03-08 | 2019-02-14 | Genzyme Corporation | Continuous purification of therapeutic proteins |
| AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| KR20150134372A (ko) * | 2013-03-29 | 2015-12-01 | 다이소 가부시키가이샤 | 세포 배양용 배지 첨가물 |
| EP3030249B1 (de) * | 2013-08-07 | 2019-12-25 | Rigshospitalet, Copenhagen University Hospital | Antikörper, verbindungen und derivate davon zur verwendung in der behandlung männlicher unfruchtbarkeit |
| PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
| SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| CA2925256C (en) | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| TWI709570B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析法及製法 |
| SG10202107077QA (en) | 2014-04-02 | 2021-07-29 | Hoffmann La Roche | Method for detecting multispecific antibody light chain mispairing |
| US10647777B2 (en) * | 2014-05-28 | 2020-05-12 | Genzyme Corporation | Methods of controlling the formation of disulfide bonds in protein solutions |
| ES2826566T3 (es) | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| EP3233907B1 (de) | 2014-12-19 | 2021-03-03 | Genmab A/S | Bispezifische heterodimere proteine aus nagern |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| ES3046837T3 (en) * | 2014-12-22 | 2025-12-02 | UCB Biopharma SRL | Method of protein manufacture |
| TWI759261B (zh) | 2015-02-27 | 2022-04-01 | 日商中外製藥股份有限公司 | Ｉｌ－６受體抗體用於製備醫藥組成物的用途 |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| ES2964640T3 (es) | 2015-08-13 | 2024-04-08 | Amgen Inc | Filtración en profundidad cargada de proteínas de unión al antígeno |
| SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
| US11312745B2 (en) * | 2016-07-22 | 2022-04-26 | Amgen Inc. | Methods of purifying Fc-containing proteins |
| WO2018018613A1 (zh) | 2016-07-29 | 2018-02-01 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| EP3620531A4 (de) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen |
| US20210363259A1 (en) * | 2017-08-22 | 2021-11-25 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| TW201923069A (zh) | 2017-10-02 | 2019-06-16 | 美商拜耳保健有限責任公司 | 以亞硒酸鹽防止細胞培養收獲物中雙硫鍵還原之方法 |
| WO2019077092A1 (en) | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES |
| IL274071B2 (en) | 2017-10-30 | 2025-10-01 | Hoffmann La Roche | Method for generating in vivo multispecific antibodies from monospecific antibodies |
| JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子 |
| US11447547B1 (en) | 2017-12-13 | 2022-09-20 | Amgen Inc. | Method of antigen-binding protein production |
| TWI827585B (zh) | 2018-03-15 | 2024-01-01 | 日商中外製藥股份有限公司 | 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法 |
| SG11202009629YA (en) | 2018-04-02 | 2020-10-29 | Amgen Inc | Erenumab compositions and uses thereof |
| US12435137B2 (en) | 2018-08-03 | 2025-10-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
| KR20250099418A (ko) * | 2018-08-15 | 2025-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | 하류 크로마토그래피에서의 재산화에 의한 단백질 단편화 제어 전략 |
| JP7699537B2 (ja) | 2018-08-31 | 2025-06-27 | ジェンザイム・コーポレーション | 無菌クロマトグラフィー樹脂および製造方法におけるその使用 |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| JP2022501325A (ja) | 2018-09-28 | 2022-01-06 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
| MX2021003976A (es) | 2018-10-11 | 2021-05-27 | Amgen Inc | Procesamiento posterior de constructos de anticuerpos biespecificos. |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| JP7736688B2 (ja) * | 2020-03-31 | 2025-09-09 | 中外製薬株式会社 | 多重特異性抗原結合分子を製造するための方法 |
| CA3173587A1 (en) | 2020-03-31 | 2021-10-07 | Chugai Seiyaku Kabushiki-Kaisha | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| WO2021207657A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| US12558423B2 (en) | 2020-05-29 | 2026-02-24 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
| WO2022056484A1 (en) * | 2020-09-14 | 2022-03-17 | Caelum Biosciences | Method of treating amyloidosis |
| WO2023043658A2 (en) * | 2021-09-14 | 2023-03-23 | Caelum Biosciences | Method of treating multiple myeloma |
| WO2024111657A1 (ja) | 2022-11-25 | 2024-05-30 | 中外製薬株式会社 | タンパク質の製造方法 |
| WO2024147150A1 (en) * | 2023-01-02 | 2024-07-11 | Zelle Biotechnology Pvt. Ltd. | Chromatographic detection, estimation and separation of amino acids in hydrolysates of monoclonal antibodies |
| CN122374330A (zh) * | 2023-12-14 | 2026-07-10 | 基因泰克公司 | 二硫亚型调节 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022902A1 (en) * | 1993-04-01 | 1994-10-13 | Schering Corporation | IN VITRO REFOLDING OF RECOMBINANT Fv FRAGMENTS |
| WO2002068455A2 (en) * | 2001-02-23 | 2002-09-06 | Immunex Corporation | Efficient recovery of correctly refolded proteins |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0293785A3 (de) | 1987-05-29 | 1990-05-02 | Oncogen Limited Partnership | Klonierung und Expression von transformierendem Affenwachstumsfaktor-SS 1 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5242687A (en) | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5169784A (en) | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
| US5266317A (en) | 1990-10-04 | 1993-11-30 | University Of Georgia Research Foundation, Inc. | Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions |
| DE4113750A1 (de) | 1991-04-26 | 1992-10-29 | Boehringer Mannheim Gmbh | Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5243041A (en) | 1991-08-22 | 1993-09-07 | Fernandez Pol Jose A | DNA vector with isolated CDNA gene encoding metallopanstimulin |
| DK0897983T3 (da) | 1991-10-25 | 2003-08-11 | Immunex Corp | Antistoffer mod CD40-L |
| AU648214B2 (en) | 1991-12-31 | 1994-04-14 | Lucky Limited | Recombinant gene coding for human alpha interferon and expression vector thereof, etc. |
| WO1995032216A1 (en) | 1994-05-25 | 1995-11-30 | University Of Nebraska Board Of Regents | Biologically active glycoprotein hormones produced in procaryotic cells |
| AU698393B2 (en) | 1994-06-24 | 1998-10-29 | Immunex Corporation | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| JPH09508140A (ja) | 1994-07-22 | 1997-08-19 | エフ・ホフマン−ラ ロシュ アーゲー | キメラｔｎｆ結合タンパク質を含有する医薬組成物 |
| NZ311335A (en) | 1995-06-07 | 1998-05-27 | Immunex Corp | Cd40l muteins and their use as ligands |
| US6063905A (en) * | 1997-01-07 | 2000-05-16 | Board Of Regents, The University Of Texas System | Recombinant human IGA-J. chain dimer |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| FR2803303B1 (fr) | 2000-01-04 | 2002-05-10 | Aventis Pasteur | Glycoproteine d'enveloppe du vih modifiee chimiquement |
| AUPQ599700A0 (en) | 2000-03-03 | 2000-03-23 | Super Internet Site System Pty Ltd | On-line geographical directory |
| EP1345968A2 (de) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Kristalle ganzer antikörper und fragmente davon und verfahren zu ihrer herstellung und verwendung |
| JP2005500304A (ja) | 2001-06-21 | 2005-01-06 | アルタス バイオロジックス インコーポレイテッド | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
| US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| KR100911951B1 (ko) | 2001-08-23 | 2009-08-13 | 젠맵 에이/에스 | 인터루킨 15 (ｉｌ-15)에 대하여 특이적인 인간 항체 |
| US9557325B2 (en) | 2003-06-09 | 2017-01-31 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of proteins by oxidation-reduction reactions |
| AU2004248155B2 (en) | 2003-06-09 | 2008-10-23 | Redox-Reactive Reagents L.L.C. | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
| WO2005073732A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Lc/ms method of analyzing high molecular weight proteins |
| EP1805320B1 (de) * | 2004-10-22 | 2014-09-03 | Amgen Inc. | Verfahren zur rückfaltung rekombinanter antikörper |
| BRPI0611600B8 (pt) * | 2005-06-17 | 2021-05-25 | Wyeth Corp | método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit |
-
2005
- 2005-10-21 EP EP05811874.6A patent/EP1805320B1/de not_active Revoked
- 2005-10-21 US US11/255,528 patent/US7928205B2/en active Active
- 2005-10-21 WO PCT/US2005/038045 patent/WO2006047340A2/en not_active Ceased
- 2005-10-21 RU RU2007118954/13A patent/RU2007118954A/ru not_active Application Discontinuation
- 2005-10-21 MX MX2007004437A patent/MX2007004437A/es active IP Right Grant
- 2005-10-21 CA CA2584211A patent/CA2584211C/en not_active Expired - Lifetime
- 2005-10-21 NZ NZ554520A patent/NZ554520A/en not_active IP Right Cessation
- 2005-10-21 KR KR1020077011651A patent/KR101370253B1/ko not_active Expired - Lifetime
- 2005-10-21 BR BRPI0517457-0A patent/BRPI0517457A/pt not_active IP Right Cessation
- 2005-10-21 AU AU2005299716A patent/AU2005299716B2/en not_active Expired
- 2005-10-21 EA EA200700917A patent/EA012162B1/ru not_active IP Right Cessation
- 2005-10-21 JP JP2007538098A patent/JP5553963B2/ja not_active Expired - Lifetime
- 2005-10-21 SG SG200907043-4A patent/SG156672A1/en unknown
-
2007
- 2007-04-17 IL IL182626A patent/IL182626A0/en unknown
- 2007-05-17 MA MA29914A patent/MA29027B1/fr unknown
- 2007-05-21 NO NO20072571A patent/NO20072571L/no not_active Application Discontinuation
-
2012
- 2012-12-25 JP JP2012281266A patent/JP2013055961A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022902A1 (en) * | 1993-04-01 | 1994-10-13 | Schering Corporation | IN VITRO REFOLDING OF RECOMBINANT Fv FRAGMENTS |
| WO2002068455A2 (en) * | 2001-02-23 | 2002-09-06 | Immunex Corporation | Efficient recovery of correctly refolded proteins |
Non-Patent Citations (8)
| Title |
|---|
| ANGAL S ET AL: "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 30, no. 1, 1 January 1993 (1993-01-01), pages 105 - 108, XP023683005, ISSN: 0161-5890, [retrieved on 19930101] * |
| BANKS DOUGLAS D ET AL: "Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity.", JOURNAL OF PHARMACEUTICAL SCIENCES FEB 2008, vol. 97, no. 2, February 2008 (2008-02-01), pages 775 - 790, XP002539396, ISSN: 0022-3549 * |
| DILLON T M ET AL: "Development of an analytical reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry method for characterization of recombinant antibodies", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 1053, no. 1-2, 17 September 2004 (2004-09-17), pages 299 - 305, XP004601197, ISSN: 0021-9673 * |
| DILLON THOMAS M ET AL: "Structural and functional characterization of disulfide isoforms of the human IgG2 subclass", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 283, no. 23, 6 June 2008 (2008-06-06), pages 16206 - 16215, XP002512405, ISSN: 0021-9258 * |
| GUO AMY ET AL: "Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype", ELECTROPHORESIS, WILEY INTERSCIENCE, DE, vol. 29, no. 12, 1 June 2008 (2008-06-01), pages 2550 - 2556, XP002512407, ISSN: 0173-0835 * |
| MCINTYRE J A ET AL: "Panitumumab. Oncolytic - Anti-EGFR human monoclonal antibody", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 29, no. 8, 1 August 2004 (2004-08-01), pages 793 - 797, XP002397423, ISSN: 0377-8282 * |
| SAPHIRE E O ET AL: "Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 319, no. 1, 24 May 2002 (2002-05-24), pages 9 - 18, XP004449639, ISSN: 0022-2836 * |
| See also references of WO2006047340A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2584211A1 (en) | 2006-05-04 |
| AU2005299716B2 (en) | 2012-09-06 |
| CA2584211C (en) | 2014-07-08 |
| AU2005299716A1 (en) | 2006-05-04 |
| WO2006047340A2 (en) | 2006-05-04 |
| US20060194280A1 (en) | 2006-08-31 |
| WO2006047340A3 (en) | 2007-07-05 |
| SG156672A1 (en) | 2009-11-26 |
| KR101370253B1 (ko) | 2014-03-05 |
| NZ554520A (en) | 2010-03-26 |
| BRPI0517457A (pt) | 2008-10-07 |
| NO20072571L (no) | 2007-07-20 |
| JP2008520190A (ja) | 2008-06-19 |
| EA012162B1 (ru) | 2009-08-28 |
| US7928205B2 (en) | 2011-04-19 |
| KR20070084483A (ko) | 2007-08-24 |
| MX2007004437A (es) | 2007-06-20 |
| EA200700917A1 (ru) | 2007-10-26 |
| IL182626A0 (en) | 2007-07-24 |
| RU2007118954A (ru) | 2008-11-27 |
| JP5553963B2 (ja) | 2014-07-23 |
| MA29027B1 (fr) | 2007-11-01 |
| EP1805320B1 (de) | 2014-09-03 |
| EP1805320A2 (de) | 2007-07-11 |
| JP2013055961A (ja) | 2013-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL182626A0 (en) | Methods for refolding of recombinant antibodies | |
| DE602006006765D1 (de) | Verfahren zur Identifizierung von GLP-1-Sekretionsförderern | |
| ATE399761T1 (de) | Verfahren zur herstellung von dinitrilen | |
| ATE408609T1 (de) | Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden | |
| ATE440888T1 (de) | Verfahren zur herstellung von glatiramer | |
| DE602005000156D1 (de) | Verfahren zur Kugeldekodierung | |
| DE602004022130D1 (de) | Verfahren zur Zeichenerkennung | |
| DE502005002364D1 (de) | Verfahren zur bestimmung relevanter objekte | |
| DE602005019848D1 (de) | Verfahren zur herstellung von tad- getrocknetem ti | |
| DE502005002345D1 (de) | Verfahren zur einstellung von sitzkomponenten | |
| DE112004001806D2 (de) | Verfahren zur Selbstjustierenden Verkleinerung von Strukturen | |
| ATE476411T1 (de) | Verfahren zur herstellung von 3-pentennitril | |
| ATE469872T1 (de) | Verfahren zur doppelbindungs-hydroisomerisierung von butenen | |
| ATE416619T1 (de) | Verfahren zur dearomatisierung von molkeprotein | |
| DE502005001881D1 (de) | Verfahren zur Kompensation von rotationsschwingungsbedingten Passerabweichungen | |
| ATE482189T1 (de) | Verfahren zur hydrocyanierung | |
| DE602005016095D1 (de) | Verfahren zur herstellung von hochreinem teicoplanin | |
| ATE394369T1 (de) | Verfahren zur aufreinigung von mesotrion | |
| ATE549314T1 (de) | Verfahren zur herstellung von 4-aminochinazolinen | |
| DE602005002420D1 (de) | Verfahren zur Bestimmung der Belastung eines Fahrzeugs | |
| ATE517069T1 (de) | Verfahren zur herstellung von leichtbeton | |
| DE602005002645D1 (de) | Alkoxylierte phosphitester und verfahren dafür | |
| AT500374A3 (de) | Verfahren zur bestimmung der produktionskosten | |
| DE602005013997D1 (de) | Verfahren zur hierarchischen kodierung von videobildern | |
| DE502005002018D1 (de) | Verfahren zur Formung von Signalspektren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20070427 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
| R17D | Deferred search report published (corrected) |
Effective date: 20070705 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 1/00 20060101AFI20070727BHEP |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ZHOU, JOE Inventor name: GADGIL, HIMANSHU, S. Inventor name: REHDER, DOUGLAS Inventor name: BONDARENKO, PAVEL Inventor name: LU,YUEFENG Inventor name: RICCI, MARGARET Inventor name: DILLON, THOMAS Inventor name: BANKS, DOUGLAS |
|
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1105984 Country of ref document: HK |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GADGIL, HIMANSHU, S. Inventor name: RICCI, MARGARET Inventor name: DILLON, THOMAS Inventor name: BANKS, DOUGLAS Inventor name: BONDARENKO, PAVEL Inventor name: REHDER, DOUGLAS Inventor name: ZHOU, JOE Inventor name: LU,YUEFENG |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20090819 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/24 20060101ALN20090811BHEP Ipc: C07K 1/113 20060101ALI20090811BHEP Ipc: C07K 16/28 20060101ALN20090811BHEP Ipc: C07K 16/00 20060101AFI20090811BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20100112 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602005044672 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12P0021060000 Ipc: C07K0016000000 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101ALN20131220BHEP Ipc: C07K 1/113 20060101ALI20131220BHEP Ipc: C07K 16/00 20060101AFI20131220BHEP Ipc: C07K 16/24 20060101ALN20131220BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20140328 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 685560 Country of ref document: AT Kind code of ref document: T Effective date: 20140915 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005044672 Country of ref document: DE Effective date: 20141016 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWALT MATTHIAS W. SCHAEFER, CH |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141204 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20140903 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150103 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150105 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602005044672 Country of ref document: DE |
|
| PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 |
|
| 26 | Opposition filed |
Opponent name: CABINET LAVOIX Effective date: 20150602 Opponent name: HOLLATZ, CHRISTIAN Effective date: 20150529 |
|
| PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
| PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150630 |
|
| R26 | Opposition filed (corrected) |
Opponent name: CABINET LAVOIX Effective date: 20150602 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141103 |
|
| PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1105984 Country of ref document: HK |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20051021 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141021 |
|
| PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
| R26 | Opposition filed (corrected) |
Opponent name: CABINET LAVOIX Effective date: 20150602 |
|
| APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
| APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
| APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
| APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
| APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
| PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
| R26 | Opposition filed (corrected) |
Opponent name: HOLLATZ, CHRISTIAN Effective date: 20150529 |
|
| APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
| APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: SPLUEGENSTRASSE 10, 8002 ZUERICH (CH) |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R064 Ref document number: 602005044672 Country of ref document: DE Ref country code: DE Ref legal event code: R103 Ref document number: 602005044672 Country of ref document: DE |
|
| APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20191008 Year of fee payment: 15 Ref country code: IE Payment date: 20191010 Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20191015 Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20191018 Year of fee payment: 15 |
|
| RDAF | Communication despatched that patent is revoked |
Free format text: ORIGINAL CODE: EPIDOSNREV1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
| RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: FI Ref legal event code: MGE |
|
| 27W | Patent revoked |
Effective date: 20190911 |
|
| GBPR | Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state |
Effective date: 20190911 |
|
| POAG | Date of filing of petition for review recorded |
Free format text: ORIGINAL CODE: EPIDOSNPRV3 |
|
| POAH | Number of petition for review recorded |
Free format text: ORIGINAL CODE: EPIDOSNPRV1 |
|
| POAI | Petitioner in petition for review recorded |
Free format text: ORIGINAL CODE: EPIDOSNPRV2 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MA03 Ref document number: 685560 Country of ref document: AT Kind code of ref document: T Effective date: 20190911 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20200925 Year of fee payment: 16 |
|
| POAD | Information related to date of filing of petition for review deleted |
Free format text: ORIGINAL CODE: EPIDOSDPRV3 |
|
| POAK | Decision taken: petition for review obviously unsubstantiated |
Free format text: ORIGINAL CODE: 0009255 |
|
| PRVN | Petition for review not allowed |
Free format text: PETITION FOR REVIEW OBVIOUSLY UNSUBSTANTIATED Effective date: 20220406 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES Effective date: 20190911 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES Effective date: 20190911 |